新冠病毒中和抗体临床试验启动 - 2020年06月08日

Shanghai has begun clinical trials on a home-grown neutralizing antibody treatment for the coronavirus, offering hope to both affected and unaffected people.
The new drug, JS016, co-developed by Shanghai Junshi Biosciences and the Institute of Microbiology under the Chinese Academy of Sciences, was approved by the National Medical Products Administration over the weekend to begin phase-1 clinical trials.
On Sunday morning, the city’s Huashan Hospital gave JS016 to healthy volunteers through veins to test the drug’s safety, immunogenicity, and how the drug moves into, through and out of the body.